首页|前列腺癌患者血清外泌体lncRNA-HOXA-AS3、miR-29a表达变化及其与患者临床特征和预后的关系

前列腺癌患者血清外泌体lncRNA-HOXA-AS3、miR-29a表达变化及其与患者临床特征和预后的关系

扫码查看
目的 观察前列腺癌(PCa)患者血清外泌体长链非编码RNA HOXA-AS3(lncRNA-HOXA-AS3)、微小RNA 29a(miR-29a)表达变化,并分析其与患者临床特征、预后的关系。方法 PCa患者115例(观察组),同期健康体检者115例(对照组),采用qRT-PCR法检测两组血清外泌体lncRNA-HOXA-AS3、miR-29a,Pearson相关分析法分析两指标间及其与患者临床特征的关系;观察组按照lncRNA-HOXA-AS3相对表达量的均数为临界值分为lncRNA-HOXA-AS3高表达者(56例)和lncRNA-HOXA-AS3低表达者(59例),按照miR-29a相对表达量的均数为临界值分为miR-29a高表达者(58例)和miR-29a低表达者(57例),采用Kaplan-Meier法绘制生存曲线,应用Log-rank检验比较高表达者和低表达者的生存率;采用Cox回归分析法分析PCa患者不良预后的危险因素。结果 与对照组比较,观察组血清外泌体lncRNA-HOXA-AS3相对表达量升高,miR-29a相对表达量降低(P均<0。05)。观察组血清外泌体lncRNA-HOXA-AS3表达与miR-29a表达呈负相关(r=-0。689,P<0。05)。血清外泌体lncRNA-HOXA-AS3、miR-29a表达均与PCa患者Gleason评分、T分期、淋巴结转移有关(P均<0。05)。与lncRNA-HOXA-AS3低表达者比较,lncRNA-HOXA-AS3高表达者患者生存率低(P<0。05);与miR-29a高表达者比较,miR-29a低表达者患者生存率低(P<0。05)。单因素及多因素分析显示,lncRNA-HOXA-AS3、miR-29a是PCa患者不良预后的影响因素和独立危险因素(P均<0。05)。结论 PCa患者血清外泌体lncRNA-HOXA-AS3表达升高、miR-29a表达下调,两者表达呈负相关,两指标均与患者Gleason评分、T分期、淋巴结转移有关,lncRNA-HOXA-AS3高表达者及miR-29a低表达者生存率低,lncRNA-HOXA-AS3、miR-29a是PCa患者不良预后的独立危险因素。
Expression changes of serum exosomes lncRNA-HOXA-AS3 and miR-29a in prostate cancer patients and their relationships with clinical characteristics and prognosis of patients
Objective To observe the expression changes of serum exosome long non-coding RNA HOXA-AS3(lncRNA HOXA-AS3)and microRNA 29a(miR-29a)in patients with prostate cancer(PCa),and to analyze their rela-tionships with clinical characteristics and prognosis of patients.Methods Totally 115 PCa patients(observation group)and 115 healthy individuals(control group)undergoing physical examinations at the same time were enrolled.The expres-sion levels of lncRNA-HOXA-AS3 and miR-29a in serum exosomes were detected by qRT-PCR.The correlation between the two indicators and their relationships with the clinical features of patients were analyzed by Pearson correlation analy-sis.The observation group was divided into the high lncRNA-HOXA-AS3 expression group(56 cases)and low lncRNA-HOXA-AS3 expression group(59 cases)according to the mean relative expression of lncRNA-HOXA-AS3,and divided into the high miR-29a expression group(58 cases)and low miR-29a expression group(57 cases)according to the mean relative expression of miR-29a.The survival curves were drawn by Kaplan-Meier method,and the survival rates of high expression group and low expression group were compared by Log-rank test.The risk factors for poor prognosis of PCa pa-tients were analyzed by Cox regression analysis.Results Compared with the control group,the relative expression level of serum exosome lncRNA-HOXA-AS3 in the observation group increased,while the relative expression level of miR-29a decreased(both P<0.05).The expression of lncRNA-HOXA-AS3 and miR-29a in the serum exosomes of the observation group was negatively correlated(r=-0.689,P<0.05).The expression of lncRNA-HOXA-AS3 and miR-29a in serum exosomes was related to Gleason score,T stage,and lymph node metastasis in PCa patients(all P<0.05).Compared with patients with low expression of lncRNA-HOXA-AS3,patients with high expression of lncRNA-HOXA-AS3 had a low-er survival rate(P<0.05);compared with those with high expression of miR-29a,patients with low expression of miR-29a had a lower survival rate(P<0.05).Univariate and multivariate analysis showed that lncRNA-HOXA-AS3 and miR-29a were independent risk factors for poor prognosis in patients with PCa(P<0.05).Conclusions The expression of ln-cRNA-HOXA-AS3 in the serum exosomes of PCa patients increases,while the expression of miR-29a is down-regulated,and the two expression levels are negatively correlated.Both indicators are related to the patient's Gleason score,T stage,and lymph node metastasis.Patients with high expression of lncRNA-HOXA-AS3 and low expression of miR-29a have a low survival rate.The lncRNA-HOXA-AS3 and miR-29a are independent risk factors for poor prognosis in PCa patients.

prostate carcinomaserum exosomeslong non-coding RNA HOXA-AS3microRNA-29a

朱研峰、刘志飞、邢力永、孟建利、谢华、石鹏、雷竹卿

展开 >

唐山市人民医院泌尿外科,河北唐山 063000

前列腺癌 血清外泌体 长链非编码RNA HOXA-AS3 微小RNA 29a

河北省医学科学研究课题计划

20220216

2024

山东医药
山东卫生报刊社

山东医药

CSTPCD
影响因子:1.225
ISSN:1002-266X
年,卷(期):2024.64(24)